How many studies have been conducted on Cd52 Antigen?

BiohacksAI has indexed 98 PubMed studies on Cd52 Antigen, including 1 randomized controlled trials (RCTs). 64% of studies involve human subjects.

What are the main research areas for Cd52 Antigen?

The primary research domains for Cd52 Antigen are 🔬 Oncology, 🛡️ Immunity, 😴 Sleep. This is based on analysis of 98 PubMed studies using the BiohacksAI evidence platform.

BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.

Cd52 Antigen

A small GPI-linked glycoprotein expressed on the surface of normal and malignant B-CELLS; T-CELLS; MONOCYTES; MACROPHAGES; NK CELLS; and GRANULOCYTES. It is expressed densely and without modulation in many malignant T-cell neoplasms and therefore a target for antibody therapies (e.g., ALEMTUZUMAB).

98+ PubMed studies analyzed · 1 RCTs · Evidence Score: 49.3

Research Domains

Cd52 Antigen has been studied across 11 research domains including 🔬 Oncology, 🛡️ Immunity, 😴 Sleep, 🫘 Kidney, 🔬 Inflammation. The primary research focus is 🔬 Oncology with 72% of studies addressing this area.

Loading evidence profile...

This evidence profile for Cd52 Antigen is generated deterministically from 98 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.